These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21426474)

  • 1. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
    Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
    BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
    de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
    BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
    Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
    Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
    Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
    Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.
    Youssef RF; Schlomer BJ; Ho R; Sagalowsky AI; Ashfaq R; Lotan Y
    Urol Oncol; 2012; 30(3):273-7. PubMed ID: 20451422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
    Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
    J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
    Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
    JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
    Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
    Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.
    Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR
    Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.